Role of adipose tissue in the development of vascular complications in type 2 diabetes mellitus

Diabetes Research and Clinical Practice

Volumn 78, Issue 3 SUPPL., 2007, Pages

  Kowalska, Irina ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Adipocytokines; Cardiovascular complications; Type 2 diabetes mellitus

Indexed keywords

ADIPONECTIN; ANGIOTENSINOGEN; CYTOKINE; FATTY ACID; LEPTIN; MONOCYTE CHEMOTACTIC PROTEIN; RESISTIN; RETINOID BINDING PROTEIN; TUMOR NECROSIS FACTOR ALPHA; VISFATIN;

ADIPOSE TISSUE; ARTICLE; BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE COURSE; FATTY ACID BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OXIDATIVE STRESS; PATHOGENESIS;

EID: 36549041940     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2007.10.007     Document Type: Article

References (113)

1. Zimmet P., Alberti K.G., and Shaw J. Global and societal implications of the diabetes epidemic. Nature 414 (2001) 782-787
2. Bronwlee M. Pathogenesis of diabetic complications. Nature 414 (2001) 813-820
3. Cerriello A. Postprandial hyperglycemia and diabetes complications: is time to treat?. Diabetes 54 (2005) 1-7
4. Crandall D.L., Hausman G.J., and Kral J.G. A review of the microcirculation of adipose tissue: anatomic, metabolic and angiogenic perspectives. Microcirculation 4 (1997) 211-232
5. Krotkiewski M., Bjorntrop P., Sjostrom L., and Smith U. Impact of obesity on metabolism in men and women: importance of regional adipose tissue distribution. J. Clin. Invest. 72 (1983) 1150-1162
6. Weisberg S.P., McCann D., Desai M., Rosenbaum M., Leibel R.L., and Ferrante Jr. A.W. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 112 (2003) 1796-1808
7. Ahima R.S., and Filer J.S. Adipose tissue as an endocrine organ. Trends Endocrinol. Metab. 11 (2000) 327-332
8. Fruhbeck G., Gomez-Ambrosi J., Muruzabal F.J., and Burrell M.A. The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. Am. J. Physiol. 280 (2001) E827-E847
9. Hotamisligil G.S., Shargill N.S., and Spiegelman B.M. Adipocyte expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 259 (1993) 87-91
10. Fried S.K., Bunkin D.A., and Greenberg A.S. Omental and subcutaneous adipose tissues of obese subject release interleukin-6: depot difference and regulation by glucocorticoid. J. Clin. Endocrinol. Metab. 83 (1998) 847-850
11. Bruun J.M., Pedersen S.B., and Richelsen B. Interleukin-8 production in human adipose tissue: inhibitory effect of anti-diabetic compounds, the thiazolidinendione ciglitazone and the biguanide metformin. Horm. Metab. Res. 32 (2000) 537-541
12. Skruk T., Kolb H., Muller-Scholze S., Rohrig K., Hauner H., and Herder C. The proatherogonic cytokine interleukin-18 is secreted by human adipocytes. Eur. J. Endocrinol. 152 (2005) 863-868
13. Zhang Y., Proneca R., Maffei M., Barone M., Leopold L., and Fridmann J.M. Positional cloning of the mouse obese gene and its human homologue. Nature 372 (1994) 425-432
14. Steppan C.M., Balley S.T., Bath S., Brown E.J., Banerjee R.R., Wright C.M., et al. The hormone resistin links obesity to diabetes. Nature 409 (2001) 307-312
15. Scherer P.E., Williams S., Fogliano M., Baldini G., and Lodish H.F. A novel serum protein similar to C1q, produced exclusively in adipocytes. J. Biol. Chem. 270 (1995) 26746-26749
16. Fukahara A., Matsuda M., Nishizawa M., Segawa K., Tanaka M., Kishimoto K., et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307 (2005) 426-430
17. Christiansen T., Richelsen B., and Bruun M. Monocyte chemoattractant protein-1 is produced in isolated adipocytes, associated with adiposity and reduced after weight loss in morbidly obese subjects. Int. J. Obes. 29 (2005) 146-150
18. Yang Q., Graham T.E., Mody N., Preitner F., Peroni O.D., Zabolotny J.M., et al. Serum retinol binding protein contributes to insulin resistance and obesity in type 2 diabetes mellitus. Nature 436 (2005) 356-362
19. Karlsson C., Lindell K., Ottoson M., Sjostrom L., Carlsson B., and Carlsson L.M.S. Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angitensin II. J. Clin. Endocrinol. Metab. 83 (1998) 3925-3929
20. Shimomura L. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat. Med. 2 (1996) 800-803
21. Wajchenberg B.L. Subcutaneous and visceral adipose tissue; their relation to the metabolic syndrome. Endocr. Rev. 21 (2000) 697-738
22. Sharma A.M., and Staels B. Peroxisome proliferators activated receptors γ (PPARγ) and adipose tissue-understanding obesity-related changes in regulation of lipid and glucose metabolism. J. Clin. Endocrinol. Metab. 92 (2007) 386-395
23. Hammerstad A., Andersson C.X., Rotter Sopaskis V., and Smith V. The effects of PPARγ ligands on the adipose tissue in insulin resistance. Prostaglandins Leukot. Essent. Fatty Acids 73 (2005) 65-75
24. Xu H., Barnes G.T., Yang Q., Tan G., Yang D., Chou C.J., et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 112 (2003) 1821-1830
25. Boden G. Fatty acid-induced inflammation and insulin resistance in skeletal muscle and liver. Curr. Diab. Rep. 6 (2006) 177-181
26. Gonzalez-Manchon C., Ayuso M.S., and Parrilla R. Control of hepatic gluconeogenesis: role of fatty acid oxidation. Arch. Biochem. Biophys. 271 (1989) 1-9
27. Kahn B.B., and Flier J.S. Obesity and insulin resistance. J. Clin. Invest. 106 (2000) 473-481
28. Roden M., Price T.B., Perseghin G., Petersen K.F., Rothman D.L., Cline G.W., et al. Mechanism of free fatty acid-induced insulin resistance in humans. J. Clin. Invest. 97 (1996) 2859-2865
29. Boden G., Lebed B., Schatz M., Homko C., and Lemieux S. Effect of acute changes on plasma free fatty acids on intramyocellular fat content and insulin resistance in healthy subjects. Diabetes 50 (2001) 1612-1617
30. Itani S.I., Ruderman N.B., Schmieder F., and Boden G. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglicerol, protein kinase C, and IkappaB-alpha. Diabetes 51 (2002) 2005-2011
31. Griffin M.E., Marcucci M.J., Cline G.W., Bell K., Barucci N., Lee D., et al. Free fatty acid induced insulin resistance is associated with activation of protein kinase C θ and alterations in insulin signaling cascade. Diabetes 48 (1999) 1270-1274
32. Ikeda Y., Olsen G.S., Ziv E., Hansen L.L., Busch A.K., Hansen B.F., et al. Cellular mechanism of nutritionally induced insulin resistance in Psammomys obesus. Overexpression of protein kinase Cε in skeletal muscle precedes the onset of hyperinsulinemia and hyperglycemia. Diabetes 50 (2001) 584-592
33. Oliver M.F. Prevention of ventricular fibrillation during acute myocardial ischemia: control of free fatty acids. J. Cardiovasc. Pharmacol. Ther. 6 (2001) 213-217
34. Tripathy D., Mohanty P., Dhindsa S., Syed T., Ghanim H., Aljada A., et al. Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes 52 (2003) 2882-2887
35. Pilz S., Scharnagl H., Tiran B., Seelhorst U., Wellnitz B., Bohem B.O., et al. Free fatty acids are independently associated with all-cause and cardiovascular mortality in subjects with coronary artery disease. J. Clin. Endocrinol. Metab. 91 (2006) 2542-2547
36. Considine R.V., Sinha M.K., Heiman M.C., Kraminnas A., Stephens T.W., Nyce M.R., et al. Serum immunoreactive-leptin concentration in normal-weight and obese humans. N. Engl. J. Med. 334 (1996) 292-295
37. Kowalska I., Stra{ogonek}czkowski M., and Kinalska I. Levels of leptin in plasma of patients with type 2 diabetes. Pol. Arch. Med. Wewn. 99 (1998) 470-476
38. Farooqi I.S., Jeeb S.A., Langmack G., Lawrence E., Cheetham C.C., Prentice A.M., et al. Effect of recombinant leptin therapy in a child with congenital leptin deficiency. N. Engl. J. Med. 341 (1999) 879-884
39. Muoio D.M., and Lynis Dohm G. Peripheral metabolic actions of leptin. Best Pract. Res. Clin. Endocrinol. Metab. 16 (2002) 653-666
40. Considine R.V. Human leptin: an adipocyte hormone with weight-regulatory and endocrine function. Semin. Vasc. Med. 5 (2005) 15-24
41. Beltowski J. Leptin and atherosclerosis. Atherosclerosis 189 (2006) 47-60
42. Ciccone M., Vettor R., Pannacciulli N., Minenna A., Ballacicco M., Rizzon P., et al. Plasma leptin is independently associated with the intima media-thickness of the common carotid artery. Int. J. Obes. 25 (2001) 805-810
43. Wolk R., Berger P., Lennon R.J., Brilakis E.S., Johnson B.D., and Somers V.K. Plasma leptin and prognosis in patients with established coronary atherosclerosis. J. Am. Coll. Cardiol. 44 (2004) 1819-1829
44. Reilly M.P., Igbal N., Schutta M., Wolfe M.L., Scally M., Localio A.R., et al. Plasma leptin levels are associated with coronary aterosclerosis in type 2 diabetes. J. Clin. Endocrinol. Metab. 89 (2004) 3782-3788
45. Le Lay S., Boucher J., Rey A., Castan-Laurell I., Krief S., Ferre P., et al. Decreased resistin expression in mice with different sensitivities to a high-fat diet. Biochem. Biophys. Res. Commun. 289 (2001) 564-567
46. Juan C.C., Au L., Fnag V., Kang S.F., Ko Y.H., Kuo S.F., et al. Suppressed gene expression of adipocyte resistin in an insulin-resistant rat model probably by elevated free fatty acids. Biochem. Biophys. Res. Commun. 289 (2001) 1328-1333
47. Nagaev I., and Smith U. Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. Biochem. Biophys. Res. Commun. 285 (2001) 561-564
48. Savage D.B., Sewter C.P., Klenk E.S., Segal D.G., Vidal-Puig A., Considine R.V., et al. Resistin/Fizz3 expression in relation to obesity and peroxisome proliferators-activated receptor-γ action in humans. Diabetes 50 (2001) 2199-2202
49. Janke J., Engeli S., Gorzelniak K., Luft F.C., and Sharma A.M. Resistin gene expression in human adipocytes is not related to insulin resistance. Obes. Res. 10 (2002) 1-5
50. Patel L., Buckels A.C., Kinghorn I.J., Murdock P.R., Holbrook J.D., Plumpton C., et al. Resistin is expressed in human macrophages and directly regulated by PPAR γ activators. Biochem. Biophys. Res. Commun. 300 (2003) 472-476
51. Young B., Yu K., Park H.J., Lee N.S., Min S.S., Youn M.Y., et al. Plasma resistin concentrations measured by enzyme-linked immunosorbent assay using a newly developed monoclonal antibody are elevated in individuals with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 89 (2004) 150-156
52. Utzschneider K.M., Carr D.B., Tong J., Wallace T.M., Hull R.L., Zraika S., et al. Resistin is not associated with insulin sensitivity or the metabolic syndrome in humans. Diabetologia 48 (2005) 2330-2333
53. Fehmann H., and Heyn J. Plasma resistin levels in patients with type 1 and type 2 diabetes mellitus and in healthy controls. Horm. Metab. Res. 34 (2002) 671-673
54. Bokarewa M., Nagaev I., Dalhberg L., Smith U., and Tarkowski A. Resistin an adipokine with potent proinflammatory cytokine properties. J. Immunol. 174 (2005) 5789-5795
55. Verma S., Li S.H., Wang C.H., Fedark P.W., Li R.K., Weisel R.D., et al. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation 187 (2003) 736-740
56. Burnett M.S., Lee C.W., Kinnaird T.D., Stabile E., Durrani S., Dullum M.K., et al. The potential role of resistin in atherogenesis. Atherosclerosis 182 (2005) 241-248
57. Reilly M.P., Lehrke M., Wolfe M.L., Rohatagi A., Lazar M.A., and Rader D.J. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 111 (2005) 932-939
58. Chandran M., Philips A.S., Ciaraldi T., and Henry R.R. Adiponectin: more than just another fat cell hormone?. Diab. Care 26 (2003) 2442-2450
59. Yamauchi T., Kamon J., Ito Y., Tsuchida A., Yokomizo T., Kita S., et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423 (2003) 762-769
60. Matsuzawa Y., Funahashi T., Kitara S., and Shimomura I. Adiponectin and metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 29-33
61. Hotta K., Funahshi T., Bodkin N.L., Ortmeyer H.K., Arita Y., Hansen B.C., et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 50 (2001) 1126-1133
62. Hotta K., Funahshi T., Arita Y., Takahashi M., Matsuda M., Okamoto Y., et al. Plasma concentration of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler. Thromb. Vasc. Biol. 20 (2000) 1595-1599
63. Lindsay R.S., Funahashi T., Hanson R.L., Matsuzawa Y., Tanaka S., Tataranni P.A., et al. Adiponectin and development of type 2 diabetes in the Pima Indian population (Letter). Lancet 360 (2002) 57-58
64. Arita Y., Kihara S., Ouchi N., Takahashi M., Maeda K., Miyagawa J., et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun. 257 (1999) 79-83
65. Kumada M., Kihara S., Sumitsuji S., Kawamoto T., Matsumoto S., Ouchi N., and Osaka CAD Study Group-Coronary Artery Disease. Association of hipoadiponectinemia with coronary artery disese in men. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 85-89
66. Adamczak W., Wie{ogonek}cek A., Funahashi T., Chudek J., Kokot F., and Matsuzawa Y. Decreased plasma adiponectin concentrations in patients with essential hypertension. Am. J. Hypertens. 16 (2003) 72-75
67. Kowalska I., Straczkowski M., Nikołajuk A., Krukowska A., Kinalska I., and Górska M. Plasma adiponectin concentration and tumor necrosis factor-α system activity in lean non-diabetic offspring of type 2 diabetic subjects. Eur. J. Endocrinol. 154 (2006) 319-324
68. Yamauchi T., Kamon J., Waki H., Terauchi Y., Kubota N., Hara K., et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 7 (2001) 941-946
69. Hayashi T., Hirshman M.F., Fujii N., Habinowski S.A., Witters L.A., and Goodyear L.J. Metabolic stress and altered glucose transport: activation of AMP-activated protein kinase as a unifying coupling mechanism. Diabetes 49 (2000) 527-531
70. Winder W.W., and Hardie D.G. AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am. J. Physiol. 277 (1999) E1-E10
71. Yamauchi T., Kamon J., Minokoshi Y., Ito Y., Waki H., Uchida S., et al. Adiponectin stimulates glucose utilization and fatty acid oxidation by activating AMP-activated protein kinase. Nat. Med. 8 (2002) 1288-1295
72. Stefan N., Vozarova B., Funahashi T., Matsuzawa Y., Weyer C., Lindsay R.S., et al. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes 51 (2002) 1884-1888
73. Pischon T., Girman C.J., Hotamisligil G.S., Rifai N., Hu F.B., and Rimm E.B. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291 (2004) 1730-1737
74. Kojima S., Funahshi T., Sakamoto T., Miyamato S., Soejima H., Hokamahi J., et al. The variation of plasma concentration of a novel, adipocyte derived protein, adiponectin, in patients with acute myocardial infarction. Heart 89 (2003) 667-668
75. Okamoto Y., Kihara S., Ouchi N., Nishida M., Arita Y., Kumada M., et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 106 (2002) 2767-2770
76. Goldstein B.J., and Scalia R. Adiponectin: a novel adipokine linking adipocytes and vascular function. J. Clin. Endocrinol. Metab. 89 (2004) 2563-2568
77. Ouchi N., Kihara S., Arita Y., Maeda K., Kuriyama H., Hotta K., et al. Adiponectin, an adipocyte-derived plasma protein, inhbits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 102 (2000) 1296-1301
78. Kowalska I., Straczkowski M., Nikołajuk A., Kinalska I., Górska M., Prokop J., et al. Plasma adiponectin and E selectin concentrations in patients with coronary heart disease and newly diagnosed disturbances of glucose metabolism. Adv. Med. Sci. 56 (2006) 94-98
79. Shibata R., Sato K., Pimentel D.R., Takemura Y., Kihara S., Ohashi K., et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2 dependent mechanism. Nat. Med. 11 (2005) 1096-1103
80. Liao Y., Takashima S., Maeda N., Ouchi N., Komamura K., Shimomura I., et al. Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism. Cardiovasc. Res. 67 (2005) 705-713
81. Shibata R., Ouchi N., Ito M., Kihara S., Shiojima I., Pimentel D.R., et al. Adiponectin-mediated modulation of hypertrophic signals. Nat. Med. 10 (2004) 1384-1389
82. Ouchi N., Shibata R., and Walsh K. Cardioprotection by adiponectin. TCM 16 (2006) 141-146
83. Bazzoni F., and Beutler B. The tumor necrosis factor ligand and receptor families. N. Engl. J. Med. 334 (1996) 1717-1725
84. Hotamisligil G.S., Arner P., Caro J.F., Atkinson R.L., and Spiegelman B.M. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J. Clin. Invest. 95 (1995) 2409-2415
85. Saghizadeh M., Ong J.M., Garvey W.T., Henry R.R., and Kern P.A. The expression of TNFα by human muscle: relationship to insulin resistance. J. Clin. Invest. 97 (1996) 1111-1116
86. Hotamisligil G.S., Peraldi P., Budavari A., Ellis R., White M.F., and Spiegelman B.M. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNFα and obesity-induced insulin resistance. Science 271 (1996) 665-668
87. Uysal K.T., Wiesbrock S.M., Marino M.W., and Hotamisligil G.S. Protection from obesity-induced insulin resistance in mice lacking TNFα function. Nature 389 (1997) 610-614
88. Mingrone G., Rosa G., Di Rocco P., Manco M., Capristo E., Castagneto M., et al. Skeletal muscle triglycerides lowering is associated with net improvement of insulin sensitivity, TNF-alpha reduction and GLUT4 expression enhancement. Int. J. Obes. 26 (2002) 1165-1172
89. Carey A.L., Bruce C.R., Sacchetti M., Anderson M.J., Olsen D.B., Saltin B., et al. Interleukin-6 and tumor necrosis factor-alpha are not increased in patients with type 2 diabetes: evidence that plasma interleukin-6 is related to fat mass and not insulin responsiveness. Diabetologia 47 (2004) 1029-1037
90. Hotamisligil G.S., Arner P., Atkinson R.L., and Spiegelman B.M. Differential regulation of the p80 tumor necrosis factor receptor in human obesity and insulin resistance. Diabetes 46 (1997) 451-455
91. Fernandez-Real J.M., Broch M., Ricart W., Casamitjana R., Gutierrez C., Vendrell J., et al. Plasma levels of the soluble fraction of tumor necrosis factor receptor 2 and insulin resistance. Diabetes 47 (1998) 1757-1762
92. Straczkowski M., Kowalska I., Stepien A., Dzienis-Straczkowska S., Szelachowska M., and Kinalska I. Increased plasma-soluble tumor necrosis factor-alpha receptor 2 level in lean nondiabetic offspring of type 2 diabetic subjects. Diab. Care 25 (2002) 1824-1828
93. Dzienis-Straczkowska S., Straczkowski M., Szelachowska M., Stepien A., Kowalska I., and Kinalska I. Soluble tumor necrosis factor-alpha receptors in young obese subjects with normal and impaired glucose tolerance. Diab. Care 26 (2003) 875-880
94. Straczkowski M., Kowalska I., Dzienis-Straczkowska S., Stepien A., Skibinska E., Szelachowska M., et al. Changes in tumor necrosis factor-alpha system and insulin sensitivity during an exercise training program in obese women with normal and impaired glucose tolerance. Eur. J. Endocrinol. 145 (2001) 273-280
95. Lattuada G., Sereni L.P., Ruggieri D., Scollo A., Benedini S., Ragogna F., et al. Postabsorptive and insulin-stimulated energy homeostasis and leucine turnover in offspring of type 2 diabetic patients. Diab. Care 27 (2004) 2716-2722
96. Escobar-Morreale H.F., Villuendas G., Botella-Carretero J.I., Sancho J., and San Millan J.L. Obesity, and not insulin resistance is the major determinant of serum inflammatory cardiovascular risk markers in pre-menopausal women. Diabetologia 46 (2003) 625-633
97. Ofei F., Hurel S., Newkirk J., Sopwith M., and Taylor R. Effects of an engineered human anti-TNFα antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 45 (1996) 881-885
98. Paquot N., Castillo M.J., Lefebvre P.J., and Scheen A.J. No increased insulin sensitivity after a single intavenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients. J. Clin. Endocrinol. Metab. 85 (2000) 1316-1319
99. Di Rocco P., Manco M., Rosa G., Greco A.V., and Mingrone G. Lowered tumor necrosis factor receptors, but not increased insulin sensitivity, with infliximab. Obes. Res. 12 (2004) 734-739
100. Kim F., Gallis B., and Corson M.A. TNFα inhibits flow and insulin signaling leading to NO production in aortic endothelial cells. Am. J. Physiol. 280 (2001) C1057-C1065
101. Youd J.M., Rattigan S., and Clark M.G. Acute impairment of insulin-mediated capillary recruitment and glucose uptake in rat skeletal muscle in vivo by TNFα. Diabetes 49 (2000) 1904-1909
102. Fernandez-Real J.M., Molina A., Broch M., Ricart W., Gutierrez C., Casamitjana R., et al. Tumor necrosis factor system activity is associated with insulin resistance and dyslipidemia in myotonic dystrophy. Diabetes 48 (1999) 1108-1112
103. Kaartinen M., Penttila A., and Kovanen P. Mast cells in rupture-prone areas of human coronary atheromas produce and store TNFα. Circulation 94 (1996) 2787-2792
104. Siwik D.A., Chang D.L.F., and Colucci W.S. Interleukin-1β and tumor necrosis factor-α decrease collagen synthesis and increase matrix metalloproteinase activity in vitro. Circ. Res. 86 (2000) 1259-1265
105. Cigolini M., Tonoli M., Borgato L., Frigotto L., Manzato F., Zeminian S., et al. Expression of PAI-1 in human adipose tissue: a role for TNFα?. Atherosclerosis 143 (1999) 81-90
106. Memon R.A., Grunfeld C., Moser A.H., and Feingold K.R. Tumor necrosis factor mediates the effects of endotoxin on cholesterol and triglyceride metabolism in mice. Endocrinology 132 (1993) 2246-2253
107. Fernandez-Real J.M., Gutierrez C., Ricart W., Castineira M.J., Vendrell J., and Richart C. Plasma levels of the soluble fraction of TNFα receptors 1 and 2 are independent determinants of total and LDL-cholesterol concentrations in healthy subjects. Atherosclerosis 146 (1999) 321-327
108. Couffinhal T., Duplaa C., Labat L., Lamaziere J.M., Moreau C., Printzeva O., et al. Tumor necrosis factor-α stimulates ICAM-1 expression in human vascular smooth muscle cells. Arterioscler. Thromb. 13 (1993) 407-414
109. Straczkowski M., Lewczuk P., Dzienis-Stra{ogonek}czkowska S., Kowalska I., Stepien A., and Kinalska I. Elevated soluble intercellular adhesion molecule-1 levels in obesity: relationship to insulin resistance and tumor necrosis factor-alpha system activity. Metabolism 51 (2002) 75-78
110. Straczkowski M., Dzienis-Straczkowska S., Stepien A., Kowalska I., Szelachowska M., and Kinalska I. Plasma interleukin-8 concentrations are increased in obese subjects and related to fat mass and tumor necrosis factor-alpha system. J. Clin. Endocrinol. Metab. 87 (2002) 4602-4606
111. Lainez B., Fernandez-Real J.M., Romero X., Esplugues E., Canete J.D., Ricart W., et al. Identification and characterization of a novel spliced variant that encodes human soluble tumor necrosis factor receptor 2. Int. Immunol. 16 (2004) 169-177
112. Fernandez-Real J.M., Straczkowski M., Lainez B., Chacon M.R., Kowalska I., Lopez-Bermejo A., et al. An alternative spliced variant of circulating soluble tumor necrosis factor-alpha receptor-2 is paradoxically associated with insulin action. Eur. J. Endocrinol. 154 (2006) 723-730
113. Fernandez-Real J.M., Botas-Cervero P., Lainez B., Ricart W., and Delgado E. An alternatively spliced soluble TNFα receptor is associated with metabolic disorders: a replication study. Clin. Immunol. 121 (2006) 236-241